What is the Apimeds Pharmaceuticals Inc. stock price forecast?

Apimeds Pharmaceuticals Inc. is currently trading at $3.00. View real-time AI analysis on Alpha Lenz.

What is Apimeds Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Apimeds Pharmaceuticals Inc. on Alpha Lenz.

What is Apimeds Pharmaceuticals Inc.'s P/E ratio?

Apimeds Pharmaceuticals Inc.'s P/E ratio is -25.0.

Apimeds Pharmaceuticals Inc.

NYSE · APUS

$3.00+1.12(+59.57%)

Ask about Apimeds Pharmaceuticals Inc.'s future dividend policy...

Alpha Chat Insight

“Apimeds Pharmaceuticals Inc. trades at a P/E of -25.0 (undervalued) with strong ROE of 209.6%.”

Ask for details →

Company Overview

Apimeds Pharmaceuticals Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of novel therapeutic solutions. The primary focus of the company is on creating innovative treatment options to address unmet medical needs in various disease areas. It engages in intensive research and development activities to bring effective pharmaceutical products to market. Apimeds Pharmaceuticals Inc. operates within the healthcare sector, impacting the biotechnology and pharmaceutical industries significantly. The company plays a crucial role in advancing drug therapies, leveraging cutting-edge technology and expertise in pharmacology to improve patient outcomes. As an integral part of the healthcare landscape, Apimeds Pharmaceuticals Inc. contributes to medical advancement and provides valuable contributions to public health.

CEOMr. Erik C. Emerson

Websitehttps://www.apimedsus.com

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Employees2

Company Statistics

FY 2024

Profile

$34.71MMarket Cap

$0.00Revenue

0.00Shares Out

2Employees

Margins

N/AGross

N/AEBITDA

N/AOperating

N/APre-Tax

N/ANet

Valuation

-24.97P/E

-25.56P/B

N/AEV/Sales

-27.75EV/EBITDA

-47.33P/FCF

Growth (CAGR)

N/ARev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-638.88%ROA

209.61%ROE

-584.77%ROIC

Financial Health

$3.46KCash & Cash Equivalents

$1.37MNet Debt

-100.96%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Apimeds Pharmaceuticals Inc. trades at a P/E of -25.0 (undervalued) with strong ROE of 209.6%.”

Ask for details →

Frequently Asked Questions

Apimeds Pharmaceuticals Inc. (ticker: APUS) is a company listed on NYSE in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 2 employees. Market cap is $35M.

The current price is $3 with a P/E ratio of -24.97x and P/B of -25.56x.

ROE is 209.61%.